Top

Journal of Endocrinological Investigation

Published in:

01-10-2015 | Original Article

A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes

Authors: C. R. de Farias, B. R. Cardoso, G. M. B. de Oliveira, I. C. de Mello Guazzelli, R. M. Catarino, M. C. Chammas, S. M. F. Cozzolino, M. Knobel

Published in: Journal of Endocrinological Investigation | Issue 10/2015

Abstract

Purpose

To analyze the impact of selenium supplementation on serum antiTPO levels and thyroid echogenicity in patients with CAT, evaluating the response in subgroups with different GPx1 genotypes.

Methods

CAT patients (n = 55) with positive antiTPO were randomized to selenomethionine (SeMet) 200 μg daily (n = 28) or placebo (n = 27) for 3 months. Assessments included GPx1 genotyping at baseline and serum levels of plasma selenium, erythrocyte GPx1 activity, antiTPO and thyroid echogenicity at baseline, and 3 and 6 months.

Results

In the SeMet group, the increase in plasma levels of selenium and erythrocyte GPx1 activity was similar among patients with different GPx1 genotypes. In the overall cohort, patients randomized to SeMet showed a 5 % decrease in antiTPO levels at 3 months (p = non-significant) and 20 % at 6 months (p < 0.001 versus 3 months). In contrast, patients in the placebo group did not show significant changes in antiTPO levels at any time point. Subgroup analysis showed that patients with different GPx1 genotypes presented comparable responses in antiTPO levels and echogenicity index to SeMet.

Conclusions

Selenium supplementation decreased serum antiTPO levels in CAT patients, with similar response among patients with different GPx1 genotypes.

Padberg S, Heller K, Usadel KH, Schumm-Draeger PM (2001) One-year prophylactic treatment of euthyroid Hashimoto’s thyroiditis patients with levothyroxine: is there a benefit? Thyroid 11(3):249–255CrossRefPubMed

Duntas LH (2008) Environmental factors and autoimmune thyroiditis. Nat Clin Pract Endocrinol Metab 4(8):454–460CrossRefPubMed

Pearce EN, Farwell AP, Braverman LE (2003) Thyroiditis. N Engl J Med 348(26):2646–2655CrossRefPubMed

Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D (2010) Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid 20(10):1163–1173CrossRefPubMed

Petricca D, Nacamulli D, Mian C, Mantero F, Cavedon E, Girelli ME, Betterle C (2012) Effects of selenium supplementation on the natural course of autoimmune thyroiditis: a short review. J Endocrinol Invest 35(4):419–424PubMed

Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW (2002) Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 87(4):1687–1691CrossRefPubMed

Gartner R, Gasnier BC (2003) Selenium in the treatment of autoimmune thyroiditis. Biofactors 19(3–4):165–170CrossRefPubMed

Duntas LH, Mantzou E, Koutras DA (2003) Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 148(4):389–393CrossRefPubMed

Turker O, Kumanlioglu K, Karapolat I, Dogan I (2006) Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 190(1):151–156CrossRefPubMed

10.

Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H (2007) The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 92(4):1263–1268CrossRefPubMed

11.

Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES (2007) Effects of 12 months treatment with l-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid 17(7):609–612CrossRefPubMed

12.

Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, Antoni A, Kletter K, Dudczak R, Willheim M (2008) No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 18(1):7–12CrossRefPubMed

13.

Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C (2010) Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 73(4):535–539

14.

Bonfig W, Gartner R, Schmidt H (2010) Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and adolescents with autoimmune thyroiditis. Sci World J 10:990–996CrossRef

15.

Krysiak R, Okopien B (2011) The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto’s thyroiditis. J Clin Endocrinol Metab 96(7):2206–2215CrossRefPubMed

16.

Anastasilakis AD, Toulis KA, Nisianakis P, Goulis DG, Kampas L, Valeri RM, Oikonomou D, Tzellos TG, Delaroudis S (2012) Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial. Int J Clin Pract 66(4):378–383CrossRefPubMed

17.

Eskes SA, Endert E, Fliers E, Birnie E, Hollenbach B, Schomburg L, Kohrle J, Wiersinga WM (2014) Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol (Oxf) 80(3):444–451CrossRef

18.

Duntas LH, Benvenga S (2015) Selenium: an element for life. Endocrine 48(3):756–775

19.

Jablonska E, Gromadzinska J, Reszka E, Wasowicz W, Sobala W, Szeszenia-Dabrowska N, Boffetta P (2009) Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur J Nutr 48(6):383–386CrossRefPubMed

20.

Rago T, Chiovato L, Grasso L, Pinchera A, Vitti P (2001) Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dsfunction in apparently healthy subjects. J Endocrinol Invest 24(10):763–769CrossRefPubMed

21.

Muller HW, Schroder S, Schneider C, Seifert G (1985) Sonographic tissue characterisation in thyroid gland diagnosis. A correlation between sonography and histology. Klin Wochenschr 63(15):706–710CrossRefPubMed

22.

Mazziotti G, Sorvillo F, Iorio S, Carbone A, Romeo A, Piscopo M, Capuano S, Capuano E, Amato G, Carella C (2003) Grey-scale analysis allows a quantitative evaluation of thyroid echogenicity in the patients with Hashimoto’s thyroiditis. Clin Endocrinol (Oxf) 59(2):223–229CrossRef

23.

Loy M, Cianchetti ME, Cardia F, Melis A, Boi F, Mariotti S (2004) Correlation of computerized gray-scale sonographic findings with thyroid function and thyroid autoimmune activity in patients with Hashimoto’s thyroiditis. J Clin Ultrasound 32(3):136–140CrossRefPubMed

24.

Hao DQ, Xie GH, Zhang YM, Tian GJ (1996) Determination of serum selenium by hydride generation flame atomic absorption spectrometry. Talanta 43(4):595–600CrossRefPubMed

25.

Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158–169PubMed

26.

Als C, Helbling A, Peter K, Haldimann M, Zimmerli B, Gerber H (2000) Urinary iodine concentration follows a circadian rhythm: a study with 3023 spot urine samples in adults and children. J Clin Endocrinol Metab 85(4):1367–1369PubMed

27.

Sandell EB, Kolthoff IM (1937) Micro-determination of iodine by a catalytic method. Microchem Acta 1:9–25CrossRef

28.

Pino S, Fang SL, Braverman LE (1996) Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Clin Chem 42(2):239–243PubMed

29.

Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC (1981) Volumetric analysis of thyroid lobes by real-time ultrasound (author’s transl). Dtsch Med Wochenschr 106(41):1338–1340CrossRefPubMed

30.

Hofling DB, Chavantes MC, Juliano AG, Cerri GG, Knobel M, Yoshimura EM, Chammas MC (2013) Low-level laser in the treatment of patients with hypothyroidism induced by chronic autoimmune thyroiditis: a randomized, placebo-controlled clinical trial. Lasers Med Sci 28(3):743–753CrossRefPubMed

31.

Schiemann U, Avenhaus W, Konturek JW, Gellner R, Hengst K, Gross M (2003) Relationship of clinical features and laboratory parameters to thyroid echogenicity measured by standardized grey scale ultrasonography in patients with Hashimoto’s thyroiditis. Med Sci Monit 9((4)):MT13–MT17PubMed

32.

Hofling DB, Chavantes MC, Juliano AG, Cerri GG, Knobel M, Yoshimura EM, Chammas MC (2012) Assessment of the effects of low-level laser therapy on the thyroid vascularization of patients with autoimmune hypothyroidism by color Doppler ultrasound. ISRN Endocrinol 2012:126720PubMedCentralPubMed

33.

Duntas LH (2010) Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 95(12):5180–5188CrossRefPubMed

34.

Schomburg L (2011) Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 8(3):160–171CrossRefPubMed

35.

McLachlan SM, Rapoport B (2014) Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 35(1):59–105PubMedCentralCrossRefPubMed

36.

Xue H, Wang W, Li Y, Shan Z, Teng X, Gao Y, Fan C, Teng W (2010) Selenium upregulates CD4(+)CD25(+) regulatory T cells in iodine-induced autoimmune thyroiditis model of NOD.H-2(h4) mice. Endocr J 57(7):595–601CrossRefPubMed

37.

Karunasinghe N, Han DY, Zhu S, Yu J, Lange K, Duan H, Medhora R, Singh N, Kan J, Alzaher W, Chen B, Ko S, Triggs CM, Ferguson LR (2012) Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr 7(2):179–190PubMedCentralCrossRefPubMed

38.

Schulz SL, Seeberger U, Hengstmann JH (2003) Color Doppler sonography in hypothyroidism. Eur J Ultrasound 16(3):183–189CrossRefPubMed

39.

Corona G, Biagini C, Rotondi M, Bonamano A, Cremonini N, Petrone L, Conforti B, Forti G, Serio M (2008) Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases. Endocr J 55(2):345–350CrossRefPubMed

40.

Chanoine JP, Neve J, Wu S, Vanderpas J, Bourdoux P (2001) Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism. J Clin Endocrinol Metab 86(3):1160–1163PubMed

41.

Zimmermann MB, Andersson M (2012) Assessment of iodine nutrition in populations: past, present, and future. Nutr Rev 70(10):553–570CrossRefPubMed

42.

Derumeaux H, Valeix P, Castetbon K, Bensimon M, Boutron-Ruault MC, Arnaud J, Hercberg S (2003) Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults. Eur J Endocrinol 148(3):309–315CrossRefPubMed

43.

Rasmussen LB, Schomburg L, Kohrle J, Pedersen IB, Hollenbach B, Hog A, Ovesen L, Perrild H, Laurberg P (2011) Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol 164(4):585–590CrossRefPubMed

44.

Brauer VF, Schweizer U, Kohrle J, Paschke R (2006) Selenium and goiter prevalence in borderline iodine sufficiency. Eur J Endocrinol 155(6):807–812CrossRefPubMed

45.

Poppe K, Velkeniers B, Glinoer D (2008) The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab 4(7):394–405CrossRefPubMed

46.

van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H (2014) Selenium supplementation for Hashimoto’s thyroiditis: summary of a Cochrane systematic review. Eur Thyroid J 3(1):25–31PubMedCentralPubMed

Title: A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes
Authors: C. R. de Farias
B. R. Cardoso
G. M. B. de Oliveira
I. C. de Mello Guazzelli
R. M. Catarino
M. C. Chammas
S. M. F. Cozzolino
M. Knobel
Publication date: 01-10-2015
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 10/2015
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0285-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

PseudoCushing: why a clinical challenge?

Expanding the therapeutic spectrum of metformin: from diabetes to cancer

Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience

1,25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats

Bone density assessment in a cohort of pediatric patients affected by 22q11DS

The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials